Satraplatin提高头颈部鳞癌放射治疗疗效的动物实验研究

Satraplatin enhanced the efficacy of radiotherapy for head and neck squamous carcinoma

目的:观察satraplatin是否能提高移植性FaDu头颈部鳞癌的放射治疗疗效。方法:建立裸鼠肿瘤模型70只,当位于每只裸鼠右大腿的肿瘤直径达到8．0 mm(7．6～8．3 mm)时开始实验。实验共分成7组(每组10只),分别是对照组、satra- platin组、放疗(radiotherapy,RT)组、satraplatin+RT(6 h后)组、satraplatin+RT(24 h后)组、RT+satraplatin(6 h后)组和RT+satraplatin(24 h后)组。观察指标为肿瘤生长延迟时间(肿瘤直径从8．0 mm生长至12．0 mm所需时间)和肿瘤治愈的情况。结果:3只荷瘤鼠在治疗过程中死亡,其余67只无治愈。观察肿瘤生长情况发现satraplatin组和放疗组的绝对延迟时间分别为(0．7±0．4)d和(5．5±1．1)d,而satraplatin+RT(6 h后)组、satraplatln+RT(24 h后)组、RT+satraplatin(6 h后)组和RT+satraplatin(24 h后)组的绝对延迟时间则分别为(8．1±1．3)、(7．8±1．1)、(6．6±1．1)和(4．3±0．6)d,其标准化的延迟时间分别为(7．4±1．3)、(7．1±1．1)、(5．9±0．6)和(3．6±0．6)d,增益因子分别为1．30、1．25、1．04和0．63。结论:实验结果显示在放疗前6或24 h应用satraplatin能提高移植性FaDu头颈部鳞癌的放射治疗疗效。

Objective：To investigate whether satraplatin can enhance the effect of radiotherapy on left and right transplanted FaDu head ＆ neck squamous xenografts or not. Methods：FaDu head ＆ neck squamus carcinoma ceils were implanted into the right leg of 70 nude mice to establish xenograft model. The experiment was carried out when the diameter of tumor reached 8.0 mm （7.6-8. 3 mm）. There were 7 experimental groups （10 mice per group）, including control, satraplatin, radiotherapy （RT）, satraplatin ＋ RT （6 h later）, satraplatin ＋RT （24 h later）, RT ＋satraplatin （6 h later）, and RT ＋ satraplatin （24 h later） group, respectively. The effect of treatment was assessed by tumor growth delay （Time in days that tumors required to grow from 8.0 to 12.0 mm） and tumor-curing rate. Results：Three mice died during the treatment course. No mice were cured at the end of experiment. For tumor growth delay analysis in the 67 mice, the absolute growth delay （AGD） for satraplatin group and RT group were （0.7±0.4） and （5.5± 1.1） d, respectively. The AGD in satraplatin＋RT （6 h later）, satraplatin ＋ RT （24 h later）, RT ＋ satraplatin （6 h later） and RT ＋ satraplatin （24 h later） group were （8.1±1.3）, （7.8±1.1）, （6.6±1. 1）, and （4.3±0.6） d, respectively. The normalized growth delay of these groups were （7.4±1.3）, （7.1±1.1）, （5.9±0.6） and （3.6±0.6） d, respectively. The enhancement factors of these groups were 1.30, 1.25, 1.04, and 0.63, respectively. Conclusion：The results suggested that satraplatin could enhance the efficacy of radiotherapy for FaDu head ＆ neck xenografts when it was administered 6 or 24 h before radiotherapy.